C 16G2
Alternative Names: Antimicrobial peptide - Armata Pharmaceuticals; C-16G2Latest Information Update: 23 Sep 2020
At a glance
- Originator C3J Therapeutics
- Developer Armata Pharmaceuticals
- Class Anti-infectives; Peptide antibiotics; Peptide fragments
- Mechanism of Action Cell membrane permeability enhancers; Cell membrane structure modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Dental caries
Most Recent Events
- 23 Sep 2020 C 16G2 is available for licensing as of 23 Sep 2020. https://www.armatapharma.com/technology/stamp-platform/
- 23 Sep 2020 Discontinued - Phase-II for Dental caries (In adolescents, In the elderly, Prevention, In adults) in USA (Buccal) (Armata Pharmaceuticals pipeline, September 2020)
- 23 Sep 2020 Discontinued - Phase-II for Dental caries (In adolescents, Prevention, In adults) in USA (Buccal) (Armata Pharmaceuticals pipeline, September 2020)